Search

Purpose: Bronchopleural fistula (BPF) is a complication that can occur after pulmonary resections onset may be early or late. This study aims to present our results using omentoplasty in the treatment of BPF. Materials and Methods: We retrospectively evaluated the data of patients who developed BPF after pulmonary resection between 2010 and 2020. The results of the patients who underwent omentoplasty during surgical revision for BPF were analyzed in terms of surgical methods used, timing of the procedure, and surgical success. Results: BPF formed in 52 (2.1%) of 2486 patients who underwent anatomical lung resection. Fourteen (26.9%) of the patients with BPF were treated with omentoplasty. All of the patients were men and the median age was 58 years (range, 27-75 years). Among the patients who underwent omentoplasty, the median time from pulmonary resection to BPF development was 22 days (range, 4-221 days). The median time from BPF development to omentoplasty was 9.5 days (range, 4-485 days). Seven (50%) of the patients developed BPF after pneumonectomy and the other 7 (50%) after lobectomy. Most post-pneumonectomy BPFs occurred after right pneumonectomy (n=6, 85.7%). BPF developing after right pneumonectomy constituted 43% of all BPFs (n=6). Surgical success was achieved in 13 (92.9%) of the 14 patients who underwent BPF closure with omentoplasty. Conclusion: Omentoplasty has low complication and high success rates and can be used safely for the treatment of BPF.

Aim:This study aimed to evaluate prognostic factors influencing survival in patients who underwent surgical resection of stage I nonsmall cell lung cancer (NSCLC) in our center.Methods:A total of 472 patients with stage I NSCLC who were operated between January 2007 and November 2018 were retrospectively analyzed in the study. Patient data was collected using hospital database. The remaining patients were divided into 2 groups: patients younger than 65 years of age (group A) and those aged 65 and over (group B).Results:The patient group comprised 80 women (16.9%) and 392 men (83.1%); 152 patients were aged 65 years or over (32.2%) and 320 patients were under 65 years of age (81.5%). The mean follow-up time was 51 months. The 5-year survival rate was 67.2% overall. Patients with stage IA1, IA2, IA3, and IB tumors had 5-year survival of 78.1%, 72.5%, 77.3%, and 56.7%, respectively (p=0.009). In multivariate analysis, advanced age (≥65 years), large cell carcinoma, left-sided surgery, and higher tumor stage were the most important prognostic factors associated with poorer survival.Conclusion:Advanced age was determined to be an independent poor prognostic factor, and sub-group analyses showed that survival outcome was better with tumors smaller than 1 cm. Based on the results of our study, we believe that the classification of stage I group should be revised in the new edition of lung cancer staging.